Anika Therapeutics (ANIK) Long-Term Deferred Tax (2018 - 2025)
Historic Long-Term Deferred Tax for Anika Therapeutics (ANIK) over the last 9 years, with Q3 2025 value amounting to $1.3 million.
- Anika Therapeutics' Long-Term Deferred Tax fell 1501.36% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 1501.36%. This contributed to the annual value of $1.2 million for FY2024, which is 2095.37% down from last year.
- According to the latest figures from Q3 2025, Anika Therapeutics' Long-Term Deferred Tax is $1.3 million, which was down 1501.36% from $1.3 million recorded in Q2 2025.
- In the past 5 years, Anika Therapeutics' Long-Term Deferred Tax ranged from a high of $1.5 million in Q1 2023 and a low of $1.2 million during Q4 2024
- Moreover, its 4-year median value for Long-Term Deferred Tax was $1.4 million (2023), whereas its average is $1.4 million.
- The largest annual percentage gain for Anika Therapeutics' Long-Term Deferred Tax in the last 5 years was 337.08% (2024), contrasted with its biggest fall of 2095.37% (2024).
- Over the past 4 years, Anika Therapeutics' Long-Term Deferred Tax (Quarter) stood at $1.4 million in 2022, then increased by 2.76% to $1.5 million in 2023, then decreased by 20.95% to $1.2 million in 2024, then rose by 6.29% to $1.3 million in 2025.
- Its Long-Term Deferred Tax stands at $1.3 million for Q3 2025, versus $1.3 million for Q2 2025 and $1.2 million for Q1 2025.